Skip to main content
Fig. 3 | BioData Mining

Fig. 3

From: A network-based drug prioritization and combination analysis for the MEK5/ERK5 pathway in breast cancer

Fig. 3

Enrichment analysis results. A-C Bar charts of significantly enriched terms from DisGeNet, GO Biological Process and GO Molecular Function in each dataset. The –log10(false discovery rate) was rescalled to between 0 and 1. DisGeNet: disease-gene network, GO: Gene Ontology. D Expression patterns of genes perturbed by Reseveratrol 150mM and ER + breast cancer in the MAPK pathway

Back to article page

BioData Mining

ISSN: 1756-0381